Unknown

Dataset Information

0

Phototheranostics of CD44-positive cell populations in triple negative breast cancer.


ABSTRACT: Triple-negative breast cancer (TNBC) is one of the most lethal subtypes of breast cancer that has limited treatment options. Its high rates of recurrence and metastasis have been associated, in part, with a subpopulation of breast cancer stem-like cells that are resistant to conventional therapies. A compendium of markers such as CD44(high)/CD24(low), and increased expression of the ABCG2 transporter and increased aldehyde dehydrogenase (ALDH1), have been associated with these cells. We developed a CD44-targeted monoclonal antibody photosensitizer conjugate for combined fluorescent detection and photoimmunotherapy (PIT) of CD44 expressing cells in TNBC. The CD44-targeted conjugate demonstrated acute cell killing of breast cancer cells with high CD44 expression. This cell death process was dependent upon CD44-specific cell membrane binding combined with near-infrared irradiation. The conjugate selectively accumulated in CD44-positive tumors and caused dramatic tumor shrinkage and efficient elimination of CD44-positive cell populations following irradiation. This novel phototheranostic strategy provides a promising opportunity for the destruction of CD44-positive populations that include cancer stem-like cells, in locally advanced primary and metastatic TNBC.

SUBMITTER: Jin J 

PROVIDER: S-EPMC4908597 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Phototheranostics of CD44-positive cell populations in triple negative breast cancer.

Jin Jiefu J   Krishnamachary Balaji B   Mironchik Yelena Y   Kobayashi Hisataka H   Bhujwalla Zaver M ZM  

Scientific reports 20160615


Triple-negative breast cancer (TNBC) is one of the most lethal subtypes of breast cancer that has limited treatment options. Its high rates of recurrence and metastasis have been associated, in part, with a subpopulation of breast cancer stem-like cells that are resistant to conventional therapies. A compendium of markers such as CD44(high)/CD24(low), and increased expression of the ABCG2 transporter and increased aldehyde dehydrogenase (ALDH1), have been associated with these cells. We develope  ...[more]

Similar Datasets

| S-EPMC7924562 | biostudies-literature
| S-EPMC10257414 | biostudies-literature
| S-EPMC9235877 | biostudies-literature
| S-EPMC5669811 | biostudies-literature
| S-EPMC4361875 | biostudies-other
| S-EPMC7068233 | biostudies-literature
2018-06-29 | PXD009738 | Pride
| S-EPMC11324313 | biostudies-literature
| S-EPMC7442809 | biostudies-literature
| S-EPMC2972557 | biostudies-literature